{"preliminary_commentary":{"by_channel":{"x_thread":12,"youtube":2,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04248452\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[],"indication":"oligometastatic HER2-negative esophageal and gastric adenocarcinoma","name":"EA2183","nct_id":"NCT04248452","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ea2183-nct04248452. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive oxaliplatin IV over 1.5 hours, leucovorin IV over 1.5 hours, and 5-fluorouracil IV over 46-48 hours on days 1 and 15. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.","label":"Arm A (FOLXFOX)","type":"EXPERIMENTAL"},{"description":"Patients receive oxaliplatin IV over 2 hours on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.","label":"Arm B (CAPOX)","type":"EXPERIMENTAL"},{"description":"One week post induction of patients in ARM A, patients undergo radiation therapy for up to 15 days. Within 2-4 weeks post radiation therapy, patients receive oxaliplatin, leucovorin, and 5-fluorouracil as in Arm A for 2 years in the absence of disease progression or unacceptable toxicity.","label":"Arm C (radiation therapy, FOLFOX)","type":"EXPERIMENTAL"},{"description":"Post induction of patients in ARM A, patients continue oxaliplatin, leucovorin, and 5-fluorouracil as in Arm A for 2 years in the absence of disease progression or unacceptable toxicity.","label":"Arm D (FOLFOX)","type":"ACTIVE_COMPARATOR"},{"description":"One week post induction of patients in ARM B, patients undergo radiation therapy for up to 15 days. Within 2-4 weeks post radiation therapy, patients receive oxaliplatin and capecitabine as in Arm B for 2 years in the absence of disease progression or unacceptable toxicity.","label":"Arm E (radiation therapy, CAPOX)","type":"EXPERIMENTAL"},{"description":"Post induction of patients in ARM B, patients continue oxaliplatin and capecitabine as in Arm B for 2 years in the absence of disease progression or unacceptable toxicity.","label":"Arm F (CAPOX)","type":"ACTIVE_COMPARATOR"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2028-03-31","type":"ESTIMATED"},"conditions":["Clinical Stage IV Esophageal Adenocarcinoma AJCC v8","Clinical Stage IV Gastric Cancer AJCC v8","Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8","Clinical Stage IVA Gastric Cancer AJCC v8","Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8","Clinical Stage IVB Gastric Cancer AJCC v8","Metastatic Esophageal Adenocarcinoma","Metastatic Gastric Adenocarcinoma","Oligometastatic Esophageal Adenocarcinoma","Oligometastatic Gastric Adenocarcinoma","Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IV Gastric Cancer AJCC v8","Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8"],"enrollment":{"count":314,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Capecitabine","otherNames":["Ro 09-1978/000","Xeloda"],"type":"DRUG"},{"name":"Fluorouracil","otherNames":["5 Fluorouracil","5 Fluorouracilum","5 FU","5-Fluoro-2,4(1H, 3H)-pyrimidinedione","5-Fluorouracil","5-Fluracil","5-FU","5FU","AccuSite","Carac","Fluoro Uracil","Fluouracil","Flurablastin","Fluracedyl","Fluracil","Fluril","Fluroblastin","Ribofluor","Ro 2-9757","Ro-2-9757"],"type":"DRUG"},{"name":"Leucovorin","otherNames":["folinic acid"],"type":"DRUG"},{"name":"Leucovorin Calcium","otherNames":["Adinepar","Calcifolin","Calcium (6S)-Folinate","Calcium Folinate","Calcium Leucovorin","Calfolex","Calinat","Cehafolin","Citofolin","Citrec","Citrovorum Factor","Cromatonbic Folinico","Dalisol","Disintox","Divical","Ecofol","Emovis","Factor, Citrovorum","Flynoken A","Folaren","Folaxin","FOLI-cell","Foliben","Folidan","Folidar","Folinac","Folinate Calcium","folinic acid","Folinic Acid Calcium Salt Pentahydrate","Folinoral","Folinvit","Foliplus","Folix","Imo","Lederfolat","Lederfolin","Leucosar","leucovorin","Rescufolin","Rescuvolin","Tonofolin","Wellcovorin"],"type":"DRUG"},{"name":"Oxaliplatin","otherNames":["1-OHP","Ai Heng","Aiheng","Dacotin","Dacplat","Diaminocyclohexane Oxalatoplatinum","Eloxatin","Eloxatine","JM-83","Oxalatoplatin","Oxalatoplatinum","RP 54780","RP-54780","SR-96669"],"type":"DRUG"},{"name":"Radiation Therapy","otherNames":["Cancer Radiotherapy","Irradiate","irradiated","Irradiation","RADIATION","Radiation Therapy, NOS","Radiotherapeutics","RADIOTHERAPY","RT","Therapy, Radiation"],"type":"RADIATION"}],"last_update":"2026-10-19","lead_sponsor":"ECOG-ACRIN Cancer Research Group","official_title":"A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-03-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall survival","timeFrame":"From the time of randomization, assessed up to 5 years post treatment"}],"references":[{"citation":"Petrelli F, Ghidini A, Ghidini M, Bukovec R, Trevisan F, Turati L, Indini A, Seghezzi S, Lonati V, Moleri G, Tomasello G, Zaniboni A. Better survival of patients with oligo- compared with polymetastatic cancers: a systematic review and meta-analysis of 173 studies. F1000Res. 2021 May 27;10:423. doi: 10.12688/f1000research.52546.4. eCollection 2021.","pmid":"35602670","type":"DERIVED"}],"start_date":{"date":"2020-05-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body","url":"https://clinicaltrials.gov/study/NCT04248452"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ea2183-nct04248452"}